PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 TRIAL
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI